Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Stream of Consciousness | Main | Return of Neowater »

February 6, 2006

J&J Shakes Things Up

Email This Entry

Posted by Derek

Well, as one of my readers noted in a comment on Friday, Johnson and Johnson seems to be doing a bit of restructuring in their drug discovery departments. I haven't seen a press release on this from the company yet, and I don't know if they're required to put one out, but it's newsworthy to people like me. Word starting going around at other companies during that working day, and more details have come out since then.

It appears that they're going to shrink their big Raritan, NJ site, at least as far as research is concerned, and consolidate things more in Spring House, PA. If my sources are correct, though, there are several hundred positions that are going to disappear in the process. I should emphasize that I don't have all the details, but that's what it's sounding like.

This is a bit unnerving, because J&J wasn't on anyone's list of companies that were having trouble. It's true that they don't have any of the huge multibillion-dollar drugs that everyone hears about, but they've always seemed like a pretty solid organization. Their presence in the medical-devices market gives them a useful non-pharma revenue stream, although the recent Guidant wrangling shows that that's not exactly a quiet, restful business, either.

Anyone with more information is welcome to add it in the comments section to this post. I hope that the folks affected will be able to land on their feet.

Comments (9) + TrackBacks (1) | Category: Business and Markets


COMMENTS

1. LNT on February 7, 2006 9:20 AM writes...

I have a friend at J&J who just got notified on Friday that he was being laid off. He said that they are closing discovery research at Raritan. I heard from him and from another friend at J&J that things at J&J aren't quite as "hunky-dory" as they appear from the outside. The percentange of J&J profits that come from pharmaceuticals is fairly small, isn't it? I wonder if in the long-term J&J will get out of pharmaceuticals alltogether and focus on other parts of thier buisness.

Permalink to Comment

2. Oldchemist on February 7, 2006 10:41 AM writes...

What I've heard mostly agrees with LNT's post, although I've heard that some transfers to Spring House are going to be possible. Even at that, the positions lost seem to be in the 100 - 150 range. I've already received a blizzard of resumes. Is anyone "safe" these days?

Permalink to Comment

3. EDCi on February 7, 2006 10:42 AM writes...

What happens to most of the people laid off when the companies in this industry restructure? Do they get reassigned to different departments/locations or do they get hired by the other companies in the same business?

Permalink to Comment

4. bob on February 7, 2006 11:38 AM writes...

A collegue of mine's spouse is one of the victims.
Both spring house and raritan are dumping oncology and GI research (so i am told).
few, if any, transfers.
severence is pay period driven, not lump sum.
and i hear a real bear of a "non-compete" severence contract.

Permalink to Comment

5. lynx on February 7, 2006 11:43 AM writes...

Here's the only news item I've seen. http://www.c-n.com/apps/pbcs.dll/article?AID=/20060204/NEWS/602040305.
My sources agree with your sources, Derek, and those above. >100 positions lost; some will be offered or allowed to bid on jobs. It's pretty disturbing - and oddly underreported.

Permalink to Comment

6. tango on February 7, 2006 1:59 PM writes...

This is surprising. I agree, J&J certainly wasn't on my radar of big companies in trouble. Any ideas why J&J have had to take this unfortunate step?

Permalink to Comment

7. Dave H on February 7, 2006 3:34 PM writes...

J&J / Janssen transdermal fentanyl went generic in 2005. This may have reduced annual revenue by upto one billion dollars.

Permalink to Comment

8. heeler on February 7, 2006 6:45 PM writes...

I was looking for info on the new in yahoo finance and saw this ironic report from morningstar -http://biz.yahoo.com/ms/060206/155720.html?.v=1

It states that J&J gets 50% of its profit from drug sales and has a strong pipeline (which is always subjective).

Good luck to the folks from J&J and to the rest of us in this business. Not only is the job market tough these days, but I never imagined when I went to grad school 20 years ago that my profession would be right up there with used car salesmen in the public's eye.

Permalink to Comment

9. tarak on February 7, 2006 8:49 PM writes...

J&J Raritan:
280 positions gone
Severance pay-2 weeks for each year of service.
Job assistance-passing around positions dated June 2005.
Last day is Feb 17.

Permalink to Comment

TRACKBACKS

Listed below are links to weblogs that reference J&J Shakes Things Up:

JnJ as I see it from Heart of the Matter
Perhaps J and J is not in trouble at all and their business model is slightly different [Read More]

Tracked on February 8, 2006 5:09 PM

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern